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Abstract: Loss-of-function mutations in the OCRL gene, which encodes the phosphatidylinositol [PI]
4,5-bisphosphate [PI(4,5)P2] 5-phosphatase OCRL, cause defective endocytosis and proximal tubule dys-
function in Lowe syndrome and Dent disease 2. The defect is due to increased levels of PI(4,5)P2 and
aberrant actin polymerization, blocking endosomal trafficking. PI 3-phosphate [PI(3)P] has been re-
cently identified as a coactivator with PI(4,5)P2 in the actin pathway. Here, we tested the hypothesis
that phosphoinositide 3-kinase (PI3K) inhibitors may rescue the endocytic defect imparted by OCRL
loss, by rebalancing phosphoinositide signals to the actin machinery. The broad-range PI3K inhibitor
copanlisib and class IA p110฀ PI3K inhibitor alpelisib reduced aberrant actin polymerization in OCRL-
deficient human kidney cells in vitro. Levels of PI 3,4,5-trisphosphate, PI(4,5)P2 and PI(3)P were all
reduced with alpelisib treatment, and siRNA knockdown of the PI3K catalytic subunit p110฀ phenocopied
the actin phenotype. In a humanized OcrlY/- mouse model, alpelisib reduced endosomal actin staining
while restoring stress fiber architecture and levels of megalin at the plasma membrane of proximal tubule
cells, reflected by improved endocytic uptake of low molecular weight proteins in vivo. Thus, our find-
ings support the link between phosphoinositide lipids, actin polymerization and endocytic trafficking in
the proximal tubule and represent a proof-of-concept for repurposing alpelisib in Lowe syndrome/Dent
disease 2.
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Loss-of-function mutations in the OCRL gene, which
encodes the phosphatidylinositol [PI] 4,5-bisphosphate
[PI(4,5)P2] 5-phosphatase OCRL, cause defective
endocytosis and proximal tubule dysfunction in Lowe
syndrome and Dent disease 2. The defect is due to
increased levels of PI(4,5)P2 and aberrant actin
polymerization, blocking endosomal trafficking. PI 3-
phosphate [PI(3)P] has been recently identified as a
coactivator with PI(4,5)P2 in the actin pathway. Here, we
tested the hypothesis that phosphoinositide 3-kinase (PI3K)
inhibitors may rescue the endocytic defect imparted by
OCRL loss, by rebalancing phosphoinositide signals to the
actin machinery. The broad-range PI3K inhibitor copanlisib
and class IA p110a PI3K inhibitor alpelisib reduced
aberrant actin polymerization in OCRL-deficient human
kidney cells in vitro. Levels of PI 3,4,5-trisphosphate, PI(4,5)
P2 and PI(3)P were all reduced with alpelisib treatment, and
siRNA knockdown of the PI3K catalytic subunit p110a
phenocopied the actin phenotype. In a humanized OcrlY/-
mouse model, alpelisib reduced endosomal actin staining
while restoring stress fiber architecture and levels of
megalin at the plasma membrane of proximal tubule cells,
reflected by improved endocytic uptake of low molecular
weight proteins in vivo. Thus, our findings support the link
between phosphoinositide lipids, actin polymerization and
endocytic trafficking in the proximal tubule and represent a
proof-of-concept for repurposing alpelisib in Lowe
syndrome/Dent disease 2.
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E
pithelial cells lining the proximal tubules (PTs) of the
kidney possess an efficient receptor-mediated endolyso-
somal pathway that recovers and processes essential sub-
stances that are filtered through the glomerulus. Congenital
disorders affecting endolysosomes cause PT dysfunction
(renal Fanconi syndrome) with urinary loss of solutes and
low-molecular-weight (LMW) proteins, often complicated
by metabolic and growth complications and development of
chronic kidney disease.1 Inactivating mutations in OCRL
have been associated with Dent disease 2 (MIM #300555), a
disorder characterized by PT dysfunction, kidney stones,
and progressive kidney failure, and with the oculocerebrore-
nal syndrome of Lowe (MIM #309000), which displays, in
addition to the PT dysfunction and kidney failure, systemic
manifestations such as congenital cataracts, cognitive
disability, and hypotonia.2-4 Current treatments for Dent dis-
ease 2 and Lowe syndrome are only supportive.
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Translational Statement
Lowe syndrome and Dent disease 2, caused by muta-
tions in the phosphoinositide lipid 5-phosphatase OCRL,
manifest with proximal tubule dysfunction and low-
molecular-weight proteinuria with only supportive care
available. Our findings reveal that the phosphoinositide
3-kinase inhibitor alpelisib, which is currently approved
for cancer therapy, alleviates the aberrant phosphoino-
sitide balance and actin phenotype associated with the
OCRL loss, causing a substantial improvement of the
endocytic machinery and absorptive capacity in cellular
systems and a humanized mouse model for Lowe syn-
drome/Dent disease 2. Given its apparent safety profile,
alpelisib is a promising candidate for drug repurposing
in Lowe syndrome and Dent disease.
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Figure 1 | PI3K inhibitors relieve aberrant actin assembly at endosomes in an OCRL-deficient human kidney (HK2) cell model. (a)
Steps of phosphoinositide lipid conversion relevant for this study indicating the conversions between PI(4,5)P2, PI(3,4,5)P2, and PI(3)P with the
most relevant enzymes in bold, most relevant conversions in solid lines, and others in dashed lines. PI(4,5)P2 is elevated in Lowe syndrome due
to the lack of 5-phosphatase activity from OCRL and is made from the phosphorylation of PI by phosphatidylinositol 4-kinases (PI4Ks) and PI(4)
P 5-kinase (PIP5K). PI(4,5)P2 is phosphorylated by class I PI3Ks to produce PI(3,4,5)P3. PI(3,4,5)P3 can be dephosphorylated to PI(4,5)P2 by PTEN
or to PI(3,4)P2 by SH-2–containing inositol 5
0 polyphosphatase (SHIP) 1 and 2, synaptojanin 1 and 2, and also OCRL, although this is (continued)
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LMW proteinuria is a consistent feature observed in
Lowe syndrome/Dent disease 2, revealing that OCRL affects
receptor-mediated endocytosis.5 OCRL encodes the phos-
phatidylinositol (PI) 4,5-bisphosphate [PI(4,5)P2] 5-
phosphatase OCRL,6 which controls lipid identity in the
endolysosomal pathway by degrading PI(4,5)P2 (Figure 1a).
Deficient degradation of PI(4,5)P2 through OCRL is
implicated in the failure to uncoat clathrin-coated vesicles
in fibroblasts, accompanied by the formation of “comet”
structures of polymerized, filamentous actin from the
resulting aberrant early endosome-like organelles.7-9 In
other cell types, most notably the PT cells of the kidney,
OCRL deficiency results in F-actin “basket” structures
surrounding aberrant endolysosomal organelles.10 The
excess F-actin blocks membrane trafficking through the
endocytic and endolysosomal pathway, and is suggested to
decrease recycling of the multiligand receptor megalin to
the apical membrane, aggravating the defect within the
endolysosomal pathway.11 In agreement with a prime role
of aberrant F-actin, defective endocytic uptake caused by
OCRL mutations is alleviated by targeting the actin ma-
chinery with latrunculin B, or by depleting actin regulatory
proteins as well as by small, interfering RNA (siRNA)-
mediated depletion of PI(4)P 5-kinase to adjust the syn-
thesis of PI(4,5)P2
7,10 (Figure 1a).
Actin polymerization is increasingly understood as
arising not only from PI(4,5)P2 but also from other
phosphoinositide lipids. For example, PI(3,4,5)P3 activates
Rho-type GTPase Rac and PI(3)P acts in conjunction with
PI(4,5)P2 to stimulate actin polymerization downstream of
another Rho-type GTPase, Cdc42.12-14 The interconversion
of these phosphoinositides is coupled to the movement of
lipids through the endocytic and endosomal pathway.
PI(4,5)P2 is phosphorylated by class I phosphatidylinositol-
30-kinase (PI3K) to PI(3,4,5)P3 at the plasma membrane
and becomes progressively dephosphorylated to PI(3,4)P2
and PI(3)P or PI(4,5)P2.
14,15 PI(3)P is enriched at
endosomes, where it is essential for their function and
predominantly made by direct by phosphorylation of PI by
class III PI3K, Vps3416 (Figure 1a). In an OCRL-deficient
retinal pigmented epithelial (RPE) cell line, actin comets
generated are reduced by treatment with PI3K inhibitors
wortmannin and Vps34-IN1, in agreement with biochem-
ical studies showing a coregulation of actin via the coin-
cidence of both PI(3)P and PI(4,5)P2.
14
The rescue of endocytosis observed when targeting the
actin machinery in OCRL patient and knockout (KO)
cells,7,10 together with upstream regulation of actin by PI3K
activity14 and the highly interconnected nature of PI con-
version, provides an intriguing possibility that class I PI3K
inhibitors may be of utility in Lowe syndrome. Such in-
hibitors, developed for cancer therapy, are approved for
clinical use17 and are thus potentially amenable for drug
repurposing. Although compounds such as copanlisib18 have
a broad specificity and side effects, recent success has been
demonstrated for more specific inhibitors. Idelalisib,19 which
targets PI3K subunit p110d, is approved for chronic lym-
phocytic lymphoma, and alpelisib, which targets p110a, is
approved for use in breast cancer.20,21 Moreover, alpelisib has
shown clinical benefit in children with PROS/CLOVES syn-
drome,22 a rare overgrowth syndrome resulting from activa-
tion of PIK3A.
Here, we tested the hypothesis that class I PI3K inhibitors
may rescue the endocytic defect due to the loss of OCRL,
using established cellular and mouse models.10,11,23 We show
that the inhibition of PI3K activity via copanlisib or alpelisib,
or siRNA-mediated depletion of the alpelisib-target catalytic
subunit p110a reduces the excess actin polymerization in
human kidney (HK2) cells deficient in OCRL. Focusing on
alpelisib as the most specific compound for clinical use, we
show that it reduces actin polymerization and improves up-
take through the endolysosomal pathway in PT cells from
humanized OcrlY/ mice in vitro. Furthermore, alpelisib
treatment in vivo alleviates proteinuria, reduces PT
=
Figure 1 | (continued) thought to be minor. PI(3,4)P2 is dephosphorylated to PI(3)P by inositol polyphosphate-4-phosphatase type I A
(INPP4A) and B. PI(3)P is also made at endosomes via the phosphorylation of PI by class III PI3K, vacuolar sorting protein Vps34. (b) Western
blots illustrating OCRL expression loss in the HK2 OCRL CRISPR knockout (KO) cell line compared with wild-type (WT) HK2 control cells with a-
tubulin as loading control. (c–e) Representative Airyscan confocal micrographs and quantification of early endosome antigen 1 (EEA1)/actin
overlap (expressed as a percentage of total detected EEA1þ vesicles) for HK2 WT or OCRL KO cells treated with either dimethylsulfoxide
(DMSO) (d) or the indicated inhibitor and fixed using the 4% formaldehyde fix. In all cases, the images illustrate a single z-slice from an
Airyscan-processed confocal stack of cells immunolabeled for EEA1 (yellow), phalloidin (actin, magenta), and 40,6-diamidino-2-phenylindole
(DAPI) (cyan). Bars ¼ 5 mm. In the quantifications, the lines indicate the mean  SEM and each data point is an individual cell. In all
experiments, treatments were applied 16 hours before fixation. In all quantifications, statistical significance was assessed by a Kruskal-Wallis (K-
W) analysis of variance with Dunn’s multiple comparisons test. (c) WT or KO cells treated with either DMSO or 100 nM of copanlisib,
demonstrating rescue of the actin-endosomal overlap. K-W test: ***P < 0.001, multiple comparisons; WT DMSO versus KO DMSO, KO DMSO
versus KO copanlisib both ***P < 0.001, WT copanlisib versus KO copanlisib P ¼ 0.44 (not significant [ns]). N ¼ 52, 85, 67, and 63 cells for WT
DMSO, WT copanlisib, KO DMSO, and KO copanlisib, respectively. (d) WT or KO cells treated with either DMSO or 10 mM of alpelisib,
demonstrating rescue of the actin-endosomal overlap. K-W test: ***P < 0.001, multiple comparisons; WT DMSO versus KO DMSO, KO DMSO
versus KO alpelisib both ***P < 0.001, WT alpelisib versus KO alpelisib. P > 0.99 (ns). N ¼ 31, 30, 43, and 41 cells for WT DMSO, WT alpelisib, KO
DMSO, and KO alpelisib, respectively. (e) WT or KO cells treated with either DMSO, 10 mM of GSK2636771, or 10 mM of idelalisib, demonstrating
that neither compound is able to significantly reduce the actin-endosomal overlap. K-W test: ***P < 0.001, multiple comparisons; WT DMSO
versus KO DMSO, ***P < 0.001, KO DMSO versus KO GSK, *P ¼ 0.04, KO DMSO versus KO idelalisib, P > 0.99 (ns). N ¼ 159, 130, 203, 122, 131,
and 145 cells for WT DMSO, WT GSK2636771, WT idelalisib, KO DMSO, KO GSK2636771, and KO idelalisib, respectively. To optimize viewing of
this image, please see the online version of this article at www.kidney-international.org.
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Figure 2 | Alpelisib effects on actin are dose-responsive and recapitulated by siRNA of PI3K p110a. (a) Representative Airyscan confocal
micrographs (fixed using the 4% formaldehyde fix and immunolabeled for early endosome antigen 1 [EEA1], yellow; actin [phalloidin],
magenta; and 40 ,6-diamidino-2-phenylindole [DAPI], cyan; bars ¼ 5 mm) and quantification of wild-type (WT) or knockout (KO) human kidney
(HK2) cells treated with dimethylsulfoxide (DMSO) or the indicated doses of alpelisib for 16 hours, demonstrating dose-responsive rescue of
the actin-endosomal overlap. In all cases, the lines indicate mean  SEM and the points indicate individual cells. N ¼ 31, 30, 71, 42, 90, 89, 41,
69, 66, and 67 cells for WT control, WT 10 mM, WT 50 mM, KO DMSO, and KO 2.5, 5, 10, 15, 25, and 50 mM alpelisib, respectively. Statistical
significance assessed by the Kruskal-Wallis (K-W) test with Dunn’s multiple comparisons test: overall ***P < 0.001, multiple comparisons; WT
DMSO versus KO DMSO, KO DMSO versus KO 5, 15, 25, and 50 mM alpelisib all ***P < 0.001, KO DMSO versus KO 2.5 mM alpelisib *P ¼ 0.0131,
KO DMSO versus KO 10 mM alpelisib **P ¼ 0.0043, WT DMSO versus both WT 10 and 50 mM alpelisib P > 0.9999 (not significant [ns]). (b)
Western blot for p110a and the loading control a-tubulin of WT or KO cells treated with either scramble (Scram.) or p110a siRNA. (c)
Representative Airyscan confocal micrographs (fixed using the 4% formaldehyde fix and immunolabeled for EEA1, yellow; actin [phalloidin],
magenta; and DAPI, cyan; bars ¼ 5 mm) and quantification of WT or KO cells treated with either scramble (S) or p110a siRNA, demonstrating
reduction of EEA1-actin overlap on p110a depletion. K-W test with Dunn’s multiple comparisons test: ***P < 0.001, multiple comparisons; WT
scramble versus KO scramble, KO scramble versus KO p110a siRNA both ***P < 0.001. N ¼ 79, 108, 93, and 131 cells, respectively. HK2, human
kidney; PI3K, phosphatidylinositol-30-kinase; siRNA, small, interfering RNA. To optimize viewing of this image, please see the online version of
this article at www.kidney-international.org.
bas i c re sea r ch M Berquez et al.: Repurposing alpelisib for Lowe syndrome
886 Kidney International (2020) 98, 883–896
Figure 3 | Levels of phosphatidylinositol (PI) 4,5-bisphosphate [PI(4,5)P2] are elevated with OCRL knockout (KO), and PI(3,4,5)P3,
PI(4,5)P2, and PI(3)P are suppressed by alpelisib treatment. In all experiments, the indicated treatments were applied 16 hours before
fixation. In the quantifications, the lines indicate the mean  SEM and each data point results from an individual cell. In all quantifications,
statistical significance was assessed by a Kruskal-Wallis (K-W) analysis of variance with Dunn’s multiple comparisons test. Bars ¼ 20 mm in all
images. (a) Representative widefield micrographs of wild-type (WT) or KO human kidney (HK2) cells treated with dimethylsulfoxide (DMSO) or
10 mM of alpelisib and then fixed with the plasma membrane fix and immunolabeled for PI(3,4,5)P3 (red) and 4
0,6-diamidino-2-phenylindole
(DAPI) (cyan), with quantification of the mean cellular PI(3,4,5)P3 labeling intensity, showing the effectiveness of alpelisib treatment on
PI(3,4,5)P3 synthesis. N ¼ 96, 128, and 109 cells for WT DMSO, WT alpelisib, KO DMSO, and KO alpelisib, respectively. K-W (continued)
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dysfunction, and rescues the cellular levels of megalin in
humanized OcrlY/ mice. These results support alpelisib as a
candidate for drug repurposing in Lowe syndrome and Dent
disease 2.
RESULTS
Class I PI3K inhibitors reduce actin aggregation in OCRL-KO
HK2 cells
We used CRISPR-Cas9 gene editing to knockout (KO)
OCRL in the HK2 cell line to allow testing of class I PI3K
inhibitors on the characteristic actin aggregation at endo-
lysosomal compartments.7,9,10,14 Western blotting verified a
98.0  0.7% reduction in OCRL expression in lysates from
the KO HK2 cells (Figure 1b). The OCRL KO recapitulated
the actin basket phenotype in the HK2 cells, as indicated by
an increased overlap between F-actin and early endosome
antigen 1 (EEA1), quantified on Airyscan confocal micro-
scopy z-stacks (Figure 1c–e). This increased overlap
observed in OCRL KO cells was reversed by treatment with
copanlisib (C), a broad-range PI3K inhibitor that targets
p110a and d and to a lesser extent the p110b and g iso-
forms (Figure 1c). By western blotting of HK2 whole cell
extracts, we found that the PI3K p110 regulatory subunits
a, b, and d were all well expressed in both wild-type (WT)
and KO cells, with only trace levels of the p110g isoform
present (Supplementary Figure S1A).
We distinguished the PI3K specificity of the inhibition of
F-actin using alpelisib (A), a selective inhibitor of p110a,
and GSK2636771 (G) and idelalisib (I), selective inhibitors
of p110b and p110d, respectively (Supplementary
Figure S1A). Although alpelisib treatment gave a similar
reduction in endosomal actin polymerization compared
with copanlisib (Figure 1d), GSK2636771 and idelalisib had
a little effect on actin accumulation (Figure 1e). The class I
PI3K inhibitors had no increased toxicity on OCRL KO
relative to unmodified cells, based on the MTT assay
(Supplementary Figure S1B).
Alpelisib and p110a knockdown rescue the actin phenotype
in HK2 cells
For our ensuing studies, we focused on alpelisib as it is the
most selective and least toxic PI3K inhibitor developed so far,
and is currently used to treat a mosaic overactivation of PI3K
class Ia in children with PROS/CLOVES syndrome.22 Alpe-
lisib reduced the actin baskets in OCRL KO HK2 cells in a
dose-responsive fashion (Figure 2a). The effects were
observed at 10 mM dosage as soon as 4 hours after treatment,
without apparent toxicity (Supplementary Figure S2). To test
whether PI3K inhibition by alpelisib was the source of the
decreased actin staining, we specifically reduced its target, the
p110a subunit, using siRNA (Figure 2b). Compared with
treatment with a control (sequence-scrambled) siRNA, siRNA
against p110a yielded a 78.3  4.8% and 68.9  7.7%
depletion of p110a protein in WT and OCRL KO HK2 cells,
respectively, reflected by a significant reduction in actin bas-
kets (Figure 2c).
Reduced levels of PI(3,4,5)P3, PI(4,5)P2, and PI(3)P in alpelisib-
treated HK2 cells
To examine how phosphoinositide lipids are affected by
OCRL KO and alpelisib treatment, we stained HK2 cells with
antibodies or protein domains against PI(3,4,5)P3, PI(3)P,
and PI(4,5)P2, using optimized fixation conditions for the
plasma membrane or intracellular staining.24,25 PI(3,4,5)P3
has a diffuse localization to the plasma membrane, and
alpelisib treatment (10 mM) induced a robust decrease in
staining for PI(3,4,5)P3 in both WT and OCRL KO cells, as
expected from its mechanism of action and specificity for
class IA PI3K p110a (Figure 3a). PI(3,4,5)P3 is expected to be
dephosphorylated progressively as membranes are endocy-
tosed and trafficked into endosomes.14,26,27 By fixing cells
such that intracellular PI(3)P is preserved,25 we found that
PI(3)P punctae were also reduced by alpelisib treatment (in a
dose-responsive fashion apparent from concentrations as low
as 10 mM for the 16-hour treatment) in both WT and OCRL
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Figure 3 | (continued) test: overall ***P < 0.001, multiple comparisons; WT DMSO versus KO DMSO, WT DMSO versus WT alpelisib, and KO
DMSO versus KO alpelisib all ***P < 0.001. (b) Representative confocal micrographs of WT or KO HK2 cells treated with either DMSO, 10 mM-,
or 50-mM alpelisib for 16 hours and then fixed with the Golgi fix and labeled using the mCh-2xFYVE PI(3)P probe (magenta) and DAPI (cyan),
with quantification of the number of PI(3)P-positive puncta detected in cells treated with a range of alpelisib concentrations, as indicated,
showing PI(3)P-positive punctae are reduced in a dose-responsive fashion. N ¼ 280, 254, 210, 287, 324, 239, 340, 250, 240, and 215 cells for WT
control, WT 10 mM, WT 50 mM, KO DMSO, and KO 2.5, 5, 10, 25, and 50 mM alpelisib, respectively. K-W test: overall ***P < 0.001, multiple
comparisons; WT DMSO versus KO DMSO, WT DMSO versus WT 10 and 50 mM alpelisib, KO DMSO versus KO 50 mM alpelisib all ***P < 0.001;
KO DMSO versus KO 2.5 and 5 mM alpelisib both P > 0.9999 (not significant [ns]); KO DMSO versus KO 10 mM alpelisib **P ¼ 0.0049; KO DMSO
versus KO 25 mM alpelisib ***P ¼ 0.0002. (c) Representative widefield micrographs of WT or KO HK2 cells treated with DMSO or 10 mM of
alpelisib and then fixed with the plasma membrane fix and immunolabeled for PI(4,5)P2 (yellow) and DAPI (cyan), with quantification of
the mean cellular PI(4,5)P2 labeling intensity, showing increased plasma membrane PI(4,5)P2 in KO cells, which is reduced by alpelisib
treatment, specifically in KO cells. N ¼ 126, 112, 85, and 116 cells for WT DMSO, WT alpelisib, KO DMSO, and KO alpelisib, respectively.
K-W test: overall ***P < 0.001, multiple comparisons; WT DMSO versus KO DMSO and KO DMSO versus KO alpelisib both ***P < 0.001; WT
DMSO versus WT alpelisib P ¼ 0.4752 (ns). (d) Representative widefield micrographs of WT or KO HK2 cells treated with DMSO or 10 mM of
alpelisib and then fixed with the 4% formaldehyde fix and immunolabeled for PI(4,5)P2 (yellow) and DAPI (cyan), with quantification of
the number of PI(4,5)P2-positive puncta, showing increased PI(4,5)P2 puncta in KO cells, which is reduced by alpelisib treatment, specifically in
KO cells. N ¼ 75, 65, 52, and 69 cells for WT DMSO, WT alpelisib, KO DMSO, and KO alpelisib, respectively. K-W test: overall ***P < 0.001,
multiple comparisons; WT DMSO versus KO DMSO and KO DMSO versus KO alpelisib both ***P < 0.001; WT DMSO versus WT alpelisib P > 0.99
(ns). a.u., arbitrary units. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
bas i c re sea r ch M Berquez et al.: Repurposing alpelisib for Lowe syndrome
888 Kidney International (2020) 98, 883–896
Figure 4 | Alpelisib alleviates actin defects of Ocrl in cultured humanized OcrlY/ mouse PTCs (mPTCs). (a) Representative maximum
intensity Z-projection confocal micrographs of OcrlY/þ or OcrlY/ mPTCs treated with dimethylsulfoxide (DMSO) or 10 mM of alpelisib for 16
hours and then fixed with the 4% formaldehyde fix and immunolabeled for actin (phalloidin) (white) and 40,6-diamidino-2-phenylindole (DAPI)
(blue), with quantification of the degree to which stress fibers are present in each condition, showing that stress fibers lost in OcrlY/ mPTCs are
rescued by alpelisib treatment. The lines indicate means  SEM, and the data points indicate each imaging region: N ¼ 5 imaging regions per
condition (each containing approximately 15–20 cells). Significance was assessed by ordinary 1-way analysis of variance (ANOVA) with Holm-
Sidak’s multiple comparison test, **P ¼ 0.001, multiple comparisons; OcrlY/þ DMSO versus OcrlY/ DMSO **P ¼ 0.002, OcrlY/ DMSO versus
OcrlY/ alpelisib **P ¼ 0.004, OcrlY/þ DMSO versus OcrlY/ alpelisib P ¼ 0.50 (not significant [ns]). Bars ¼ 20 mm. (b) High-magnification
representative 3D surface renderings of Ocrl mPTCs treated with DMSO or 10 mM of alpelisib for 16 hours and then fixed with the 4%
formaldehyde fix and immunolabeled for early endosome antigen 1 (EEA1) (purple), actin (phalloidin, yellow), and DAPI (blue), and
quantification illustrating rescue of the actin-endosomal overlap by alpelisib. Lower-magnification views indicating overviews of (continued)
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KO cells (Figure 3b and Supplementary Figure S2C). As ex-
pected, the KO of OCRL in HK2 cells induced a marked in-
crease in the levels of PI(4,5)P2 both at the plasma membrane
(Figure 3c) and intracellularly (Figure 3d), compared with
WT cells.10,28 Treatment with alpelisib markedly reduced the
elevation of PI(4,5)P2 generated by OCRL KO in both com-
partments, whereas it had no effect in WT cells (Figure 3c and
d). Alpelisib is reported to inhibit PI 4-kinase b with a 50%
inhibitory concentration of 0.5 mM,19 which is a possible
source of the reduction in PI(4,5)P2. Collectively, our data
suggested that alpelisib inhibits actin assembly on OCRL KO
endosomes via a bispecific effect on the PI(4,5)P2 and PI(3)P
levels.
Alpelisib reduces intracellular phosphoinositides and
alleviates cytoskeletal defects in OcrlY/ mPTCs
We next tested whether alpelisib had the same effects in
primary cells of PT cells derived from the humanized Ocrl-
deficient mouse model (OcrlY/), which recapitulates the
abnormal actin polymerization and endocytic defect observed
in patient-derived cells.10,11 The mouse PTCs (mPTCs)
expressed similar class I PI3K regulatory subunits to HK2 cells
in both WT and OcrlY/ mice, and displayed a similar toxicity
profile toward alpelisib when assessed by MTT assays
(Supplementary Figure S3). Imaging by confocal microscopy
revealed a striking disruption of the normal F-actin stress
fiber architecture in mPTCs from OcrlY/ compared with
OcrlY/þ mice, likely due to the relocation of actin regulatory
proteins from their normal cellular locations to endosomes,
as large assemblies of actin surround these organelles and are
thought to be the origin of the trafficking defect.10,29 Treat-
ment of OcrlY/ mPTCs with alpelisib (10 mM) restored the
stress fiber architecture (Figure 4a).
As the main problem in Lowe syndrome and Dent disease
2 is reduced endosomal trafficking and consequent megalin
degradation, we sought to distinguish endosomal actin from
the stress fibers. We collected laser-scanning confocal z-stacks
throughout the cells, reconstructed the staining pattern in 3D
surface renderings, and used size shape/parameters to identify
punctate actin structures and the degree to which they over-
lapped with endosomal structures (Supplementary Figure S4
and Movies S1–S3). This analysis revealed that treatment
with alpelisib decreased aberrant polymerization of F-actin at
endosomes stained with EEA1, distinct from the stress fiber
architecture (Figure 4b). The mPTCs derived from OcrlY/
mice showed significant changes in intracellular staining for
PI(3)P (decreased) and PI(4,5)P2 (increased), compared with
mPTCs from WT OcrlY/þ mice (Figure 4c and d). Treatment
of mPTCs from OcrlY/ mice with alpelisib resulted in a
significant reduction in intracellular PI(3)P and PI(4,5)P2
staining (Figure 4c and d).
Alpelisib improves endocytic uptake in OcrlY/ mPTCs
We next assessed whether the effect of alpelisib on the cyto-
skeletal and vesicular defects observed in mPTCs resulted in
changes in the endocytic uptake capacity. To differentiate the
effect of alpelisib on binding and/or internalization of the
ligand, mPTCs were first incubated with labeled bovine serum
albumin (BSA), to induce binding of the probe with the
endocytic receptors, and then incubated with growth me-
dium, to follow the internalization of albumin (Figure 5a).
The OcrlY/ cells showed a lower plasma membrane binding
of Alexa 488-bovine serum albumin along with impaired
internalization of albumin compared with OcrlY/þ cells.
Treatment with alpelisib rescued both the binding and the
uptake of albumin in the OcrlY/ cells, with a 50% overall
rescue of endocytic uptake (Figure 5b and c). These data were
supported by the measurement of total albumin uptake
(Supplementary Figure S5a and b). We noted that the inter-
nalized/bound Alexa 488-bovine serum albumin ratio
remained similar between the different conditions
(Figure 5d), implying that the reduced uptake of albumin is
mainly due to impaired binding rather than a defective
internalization process per se.
Alpelisib improves PT dysfunction and receptor-mediated
endocytosis in OcrlY/ mice
We tested the potential therapeutic effect of alpelisib on PT
dysfunction in vivo. Ocrl mice were administered with either
vehicle or alpelisib (50 mg/kg body weight per day) by oral
gavage for 6 weeks (Figure 6a). This regimen was chosen
according to previous in vivo studies demonstrating efficacy
=
Figure 4 | (continued) these regions are shown in Supplementary Figure S4B and Supplementary Movies S1–S3. Lines indicate mean  SEM.
N ¼ 42, 47, and 45 randomly selected fields for OcrlY/þ þ DMSO, OcrlY/ þ DMSO, and OcrlY/ þ alpelisib conditions, respectively, in each case
pooled from 4 mouse kidneys per condition. Significance was tested by Kruskal-Wallis (K-W) ANOVA with Dunn’s multiple comparisons test:
overall ***P < 0.001, multiple comparisons; OcrlY/þ DMSO versus OcrlY/ DMSO and OcrlY/ DMSO versus OcrlY/ alpelisib ***P < 0.001;
OcrlY/þ DMSO versus OcrlY/ alpelisib P > 0.99 (ns). Bars ¼ 1 mm. (c) Representative confocal micrographs of OcrlY/þ or OcrlY/ mPTCs treated
with DMSO or 10-mM alpelisib and then fixed with the Golgi fix and labeled using the mCh-2xFYVE PI(3)P probe (magenta) and DAPI (cyan),
with quantification of the number of PI(3)P-positive puncta detected in cells. N ¼ 188, 177, 246, and 206 cells from OcrlY/þ þ DMSO,
OcrlY/þ þ alpelisib, OcrlY/ þ DMSO, and OcrlY/ þ alpelisib, respectively; cells were pooled from 3 Ocrl kidneys per group. K-W test: overall
***P < 0.001, multiple comparisons; OcrlY/þ DMSO versus OcrlY/ DMSO, OcrlY/þ DMSO versus OcrlY/þ alpelisib, and OcrlY/ DMSO versus
OcrlY/ alpelisib, all ***P < 0.001. Bars ¼ 20 mm. (d) Representative confocal micrographs of OcrlY/þ or OcrlY/ mPTCs treated with DMSO or 10
mM of alpelisib for 16 hours then fixed with the 4% formaldehyde fix and immunolabeled for phosphatidylinositol (PI) 4,5-bisphosphate [PI(4,5)
P2] (yellow) and DAPI (cyan), with quantification of the number of PI(4,5)P2-positive puncta, showing increased PI(4,5)P2 puncta in Ocrl
Y/ cells,
which is reduced by alpelisib treatment. N ¼ 477, 444, 423, and 494 from OcrlY/þ þ DMSO, OcrlY/þ þ alpelisib, OcrlY/ þ DMSO, and OcrlY/ þ
alpelisib, respectively; cells were pooled from 3 Ocrl kidneys per group. K-W test: overall ***P < 0.001, multiple comparisons; OcrlY/þ DMSO
versus OcrlY/ DMSO, OcrlY/þ DMSO versus OcrlY/þ alpelisib, and OcrlY/ DMSO versus OcrlY/ alpelisib, all ***P < 0.001. Bars ¼ 20 mm.
To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
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Figure 5 | Alpelisib improves endocytic uptake of humanized OcrlY/ mouse PTCs (mPTCs). (a) Schematic illustrating the pulse-chase
experiment used to examine the binding and internalization of Alexa 488-bovine serum albumin (BSA) into mPTCs. Cells were exposed to
Alexa 488-BSA (0.2 mg/ml) for 1 hour at 4 C to allow BSA to bind to cell surface receptors (pulse) and then warmed to 37 C in cell medium for
20 minutes before fixation to allow ligand internalization (chase). (b) Representative confocal micrographs of OcrlY/þ or OcrlY/mPTCs treated
with dimethylsulfoxide (DMSO) or 10 mM of alpelisib for 16 hours and subjected to the Alexa 488-BSA (green) pulse-chase experiment, before
being fixed and labeled for 40,6-diamidino-2-phenylindole (DAPI) (blue). The pulse phase of the experiment is shown in the top panel for each
condition, with the chase below. Bars¼ 20 mm. (c) Quantification of cell surface Alexa 488-BSA (i) and internalized Alexa 488-BSA (ii), evaluated
as mean fluorescence intensities per cell. Alpelisib rescues the rescued BSA binding and internalization observed in OcrlY/ cells. N¼ 209, 228,
186, and 196 cells for OcrlY/þ DMSO, OcrlY/þ alpelisib, OcrlY/ DMSO, and OcrlY/ alpelisib conditions, respectively in (i) and N ¼ 203, 183, 199,
and 233 cells for OcrlY/þ DMSO, OcrlY/þ alpelisib, OcrlY/ DMSO, and OcrlY/ alpelisib conditions, respectively in (ii), in each case pooled from 2
mouse kidneys per condition; each data point represents themean fluorescence intensity in an individual cell. Significancewas tested by Kruskal-
Wallis (K-W) analysis of variance (ANOVA)withDunn’smultiple comparisons test: for (i) cell surface BSA, overall ***P< 0.001, multiple comparisons:
OcrlY/þ DMSO versus OcrlY/ DMSO and OcrlY/ DMSO versus OcrlY/ alpelisib ***P < 0.001; OcrlY/þ DMSO versus OcrlY/þ alpelisib P ¼ 0.60 (not
significant [ns]); for (ii) internalized BSA, overall ***P< 0.001, multiple comparisons: OcrlY/þ DMSO versus OcrlY/ DMSO and OcrlY/ DMSO versus
OcrlY/ alpelisib ***P< 0.001;OcrlY/þDMSO versusOcrlY/þ alpelisib P¼ 0.66 (ns). (d) Quantification of the ratio between the cell surface Alexa 488-
BSA and the internalized Alexa 488–BSA fluorescence intensities, showing no significant differences in ratios between each condition. Each point
represents the average of the ratio in a field containing approximately 15–20 cells (N ¼ 13, 13, 10, and 11 randomly selected fields for OcrlY/þ
DMSO, OcrlY/þ alpelisib, OcrlY/ DMSO, and OcrlY/ alpelisib conditions, respectively, in each case pooled from 2 mouse kidneys per condition).
Significance was tested by K-W ANOVA with Dunn’s multiple comparisons test: overall P¼ 0.46 (ns), multiple comparisons: OcrlY/þ DMSO versus
OcrlY/ DMSO and OcrlY/ DMSO versus OcrlY/ alpelisib P> 0.99 (ns); OcrlY/þ DMSO versus OcrlY/þ alpelisib P¼ 0.84 (ns). To optimize viewing of
this image, please see the online version of this article at www.kidney-international.org.
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Figure 6 | Alpelisib improves the proximal tubule (PT) function of OcrlY/L mice, restoring ligand uptake and megalin expression. (a)
Experimental setup. Ocrlmice were treated for 6 weeks with a daily oral dose of either carboxymethylcellulose 1% (vehicle) or alpelisib (50 mg/
kg body weight). On the last day of the treatment, mice were injected with Cy5-labeled b-lactoglobulin (N ¼ 6 OcrlY/, or 8 OcrlY/ mice per
group). (b–d) The D values shown indicate the mean change from BL to D42 for the condition  SEM. (b) Clara cell protein 16 (CC16), (c)
albumin urinary output (both within 15 hours), and (d) body mass was measured in OcrlY/ mice treated with either vehicle or alpelisib at the
indicated time point. Each dot represents 1 mouse. Significance was assessed by 2-tailed paired Student’s t test; in (b) CC16 (continued)
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and safety.22,30 In line with alpelisib administration being
known to cause insulin resistance and hyperglycemia,22
alpelisib treatment led to a significant increase in glycosuria
in both Ocrl Y/þ and Ocrl Y/ mice, which could be considered
as a biomarker for drug dosing (Supplementary Table S1).
After 6 weeks of alpelisib treatment, the OcrlY/ mice dis-
played a significant reduction in the urinary excretion of the
LMW proteins CC16 (34%) and albumin (38%),
compared with vehicle-treated controls (Figure 6b and c),
whereas volume of urine and other parameters were unaf-
fected (Supplementary Table S1). Alpelisib-treated mice of
both genotypes showed a similar reduction in growth rate
relative to control mice, as previously described.22 Neverthe-
less, both vehicle and treated mice gained body weight,
indicating that the drug does not severely affect postnatal
development (Figure 6d and Supplementary Table S1).
To test whether the effect of alpelisib on LMW proteinuria
reflected recovery of receptor-mediated endocytosis in PT
cells, we followed the in vivo uptake of Cy5-labeled b-lacto-
globulin in a mouse kidney. Alpelisib-treated OcrlY/ mice
displayed a significant rescue of Cy5-labeled b-lactoglobulin
uptake, close to the extent of internalization observed in
vehicle-treated OcrlY/þ mice (Figure 6e). This was mirrored
by a significant rescue in expression of the endocytic receptor
megalin in PT cells, as observed by immunolabeling and
western blotting of the kidney lysates of alpelisib-treated
OcrlY/ mice; note that there was no change in expression
of the PT marker AQP1 (Figure 6f and g and Supplementary
Figure S5C and D). These data show that the PI3K inhibitor
alpelisib induces a substantial improvement of the PT endo-
cytic machinery and reduces LMW proteinuria in a human-
ized mouse model for Lowe syndrome.
DISCUSSION
There is currently no treatment to alleviate the defective
endocytosis causing PT dysfunction in Lowe syndrome and
Dent disease 2. Our findings reveal that alpelisib alleviates the
aberrant actin phenotype by reducing levels of PI(4,5)P2 and
PI(3)P, causing a substantial improvement of the endocytic
machinery and absorptive capacity in cellular systems and a
humanized mouse model for Lowe syndrome/Dent disease 2.
These results support the link between phosphoinositide
lipids, actin polymerization, and endocytic trafficking, with
immediate relevance for highly active epithelial cells involved
in crucial homeostatic processes (Figure 7). Given the lack of
effective therapies and the apparent safety of this class of PI3K
inhibitors, alpelisib is a promising candidate for drug repur-
posing in Lowe syndrome and Dent disease.
LMW proteinuria is the most consistent feature encoun-
tered in patients with Lowe syndrome and Dent disease 2 due
to inactivating mutations in OCRL.4 These LMW proteins can
readily be detected and quantified, offering a faithful
biomarker of defective receptor-mediated endocytosis in PT
cells.1 LMW proteinuria is particularly relevant, as it is
detected more consistently and often earlier than other sol-
utes (e.g., glucose, phosphate, amino acids) being part of the
classical “renal Fanconi syndrome”—at least in congenital
disorders of the endolysosomal pathway.1 Here, we show that
alpelisib rescues the apical endocytic uptake capacity of PT
cells in vitro and in vivo, due to restored levels of megalin
receptor at the plasma membrane. This effect is reflected by
significant reductions in the urinary loss of LMW proteins
(CC16 and albumin) in OcrlY/ mice treated with alpelisib for
6 weeks. These effects of alpelisib have been observed in
mPTCs, which keep their apical differentiation and are
particularly well suited to investigate receptor-mediated
endocytosis in physiology and disease.9 In particular, we ob-
tained mPTCs from a humanized mouse model expressing
human INPP5B in OcrlY/;Inpp5b/ background, which al-
lows us to investigate the specific consequences of the loss of
OCRL activity.11,23
The rescue of endocytosis by alpelisib is explained by its
effect on actin machinery, clearly evidenced in OCRL KO
HK2 cells and mPTCs. Our observations thus confirm and
extend previous studies showing the link between control of
the phosphoinositide balance and F-actin in the early
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Figure 6 | (continued) output change relative to baseline; þ vehicle, P ¼ 0.9802 (not significant [ns]), þ alpelisib, *P ¼ 0.0334; in (c) albumin
output change relative to baseline; þ vehicle, P ¼ 0.0502 (ns), þ alpelisib, ***P ¼ 0.0006; in (d) body mass change relative to baseline; þ
vehicle, ***P < 0.0001, þ alpelisib, **P ¼ 0.0083. (e) Representative confocal micrographs showing Cy5-labeled b-lactoglobulin (magenta) 15
minutes after tail vein injection and labeled for 40,6-diamidino-2-phenylindole (DAPI) (cyan), plus quantification of the corresponding
fluorescent signals from Ocrl mouse kidneys (N ¼ 412, 500, and 588 tubules, respectively, for OcrlY/þþ vehicle, OcrlY/ þ vehicle, and
OcrlY/ þ alpelisib) for 3 mice per treatment group. b-Lactoglobulin uptake is rescued by alpelisib treatment. Bars ¼ 20 mm. In the
quantifications, each dot represents fluorescence intensity normalized by tubule area; plotted data indicate the mean  SEM. Significance was
assessed by the Kruskal-Wallis (K-W) test followed by Dunn’s multiple comparison test; ***P < 0.001, multiple comparisons; OcrlY/þþ vehicle
versus OcrlY/ þ vehicle and OcrlY/ þ vehicle versus OcrlY/ þ alpelisib, both ***P < 0.001. (f) Western blotting and densitometry analysis
of megalin levels in whole kidney lysates from Ocrlmice. a-Tubulin was used as a loading control. The reduced megalin expression in OcrlY/ is
rescued by alpelisib. In the quantification of the densitometry analysis, each dot represents 1 mouse (N ¼ 4 OcrlY/þþ vehicle and
OcrlY/ þ vehicle and N ¼ 3 OcrlY/ þ alpelisib mice); lines indicate mean  SEM. Significance was assessed by 2-tailed unpaired Student’s t
tests: OcrlY/þþ vehicle versus OcrlY/ þ vehicle; **P ¼ 0.0057, OcrlY/ þ vehicle versus OcrlY/ þ alpelisib, *P ¼ 0.0246. (g) Representative
confocal micrographs with high-magnification insets and quantification of megalin (yellow) intensity in AQP1þ PTs (magenta) from Ocrl
kidneys also labeled for DAPI (cyan) illustrating rescue of megalin levels after alpelisib treatment. Bars ¼ 20 mm. In the quantifications, each dot
represents fluorescence intensity normalized by tubule area; plotted data indicate the mean  SEM; N ¼ 142, 191, and 266 tubules,
respectively, for OcrlY/þþ vehicle, OcrlY/ þ vehicle, and OcrlY/ þ alpelisib for 3 mice per treatment group. Significance was assessed by K-W
analysis of variance followed by Dunn’s multiple comparison test; overall ***P < 0.001, multiple comparisons; OcrlY/þþ vehicle versus
OcrlY/ þ vehicle and OcrlY/ þ vehicle versus OcrlY/ þ alpelisib, both ***P < 0.001. To optimize viewing of this image, please see the online
version of this article at www.kidney-international.org.
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endosomal pathway in OCRL patient and KO cells.7,10 The
functional loss of OCRL activity impairs the degradation of
PI(4,5)P2, which, in turn, leads to a failure to uncoat clathrin-
coated vesicles resulting in aberrant endosomal organelles in
various cell types including the PT cells.7-10 We recently
showed that the excess F-actin decreases the recycling of the
multiligand receptor megalin to the apical membrane of PT
cells, causing defective endocytosis and LMW proteinuria.11
Our data indicate that the mechanism of action of alpelisib
on endosomal actin arises from a bispecific effect of alpelisib
inhibition: first on production of PI(3,4,5)P3 and its conver-
sion to PI(3)P, and second on production of PI(4,5)P2. The
decrease in PI(4,5)P2 levels directly counteracts the OCRL
deficiency and is in agreement with previous work alleviating
excess actin and increasing endocytic flux by reduction in the
levels of phosphatidylinositol 4-phosphate 5-kinase, an
enzyme that generates PI(4,5)P2.
10 Alpelisib has a 0.5 mM
50% inhibitory concentration on the PI(4,5)P2 generating
kinase PI4Kb, which may be responsible, or it could result
from more general effects on phosphoinositide balance
resulting from the combination of OCRL KO and alpelisib
treatment. We have identified that class IA PI3K inhibition by
alpelisib is relevant to actin inhibition as siRNA-mediated
depletion of p110a inhibits actin accumulation similarly to
alpelisib treatment and copanlisib (which is not reported to
inhibit PI4Ks). In RPE cells we have previously observed that
siRNA of INPP4A, which converts PI(3,4)P2 to PI(3)P, in-
hibits actin assembly in OCRL KO cells, providing a pathway
from inhibition of PI(3,4,5)P3 production to a decrease in
endosomal PI(3)P. We showed that some PI(3)P remains,
presumably the pool produced at the early endosome by class
III PI3K, Vps34, because we found that endosomal trafficking
is enhanced rather than suppressed by alpelisib treatment.
The complex coregulation of PI metabolism and its relevance
for OCRL inactivation has also been highlighted in a recent
study where noncatalytic functions of phosphoinositide 3-
phosphatase PTEN activates PI(4,5)P2 degradation via
PLCXD, alleviating cellular phenotypes and absorption of li-
gands in a zebrafish model.31
The alleviation of the actin phenotype by reduced levels of
PI(4,5)P2 and PI(3)P by alpelisib treatment agrees with the
synergistic action of PI(4,5)P2 and PI(3)P in recruiting SNX9
to activate the actin machinery at Ocrl endosomes,14 sug-
gesting a very effective match of alpelisib specificity to
manipulate the molecular regulation of actin activation at
endosomes. In turn, as previously demonstrated, reduced
Figure 7 | Proposed model depicting the therapeutic effect of alpelisib on proximal tubule cells in Lowe syndrome. Proximal tubule
cells reabsorb urinary ligands (e.g., albumin and low-molecular-weight proteins) through megalin-mediated endocytosis. The 5-phosphatase
activity of OCRL regulates the transition from high phosphatidylinositol (PI) 4,5-bisphosphate [PI(4,5)P2] at the plasma membrane to low
levels at the early endosome with a transient coincidence of PI(4,5)P2 and PI(3)P in the vesicles. Once in the early endocytic compartment, the
ligands dissociate from the receptors and are delivered to the lysosome for degradation, whereas the receptors recycle back to the plasma
membrane for a new cycle of cargo binding. The loss of OCRL leads to an ectopic accumulation of PI(4,5)P2 at the endosomal compartment, which
results in a persistent coincidence with PI(3)P. We suggest that this event is responsible for aberrant F-actin polymerization blocking endocytic
recycling and preventing ligand reabsorption (middle panel). Alpelisib rebalances the levels of PI(4,5)P2 and PI(3)P, which results in decreased actin
polymerization and improvement of the endocytic machinery and absorptive capacity of proximal tubule cells (right panel).
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endosomal actin assembly in turn leads to an improvement in
PT endocytosis in OCRL-deficient cells.10 Further character-
ization will be needed to better understand whether regula-
tion of actin through phosphoinositide metabolism is the true
source of the therapeutic effect that we observe with alpelisib
in the OcrlY/ mouse model. Because class I PI3K regulate
pathways control cell growth, proliferation, survival, meta-
bolism, and autophagy,32 we cannot exclude that the endo-
cytic rescue is due to effects on PI(3,4,5)P3 directly and the
combined effect on other pathways modulated by class I
PI3K. More work is also needed to test whether PI3K in-
hibitors might also alleviate the neurologic and other clinical
manifestations of patients harboring OCRL mutations.4
The recent experience of alpelisib in pediatric patients with
PROS/CLOVES syndrome suggests that the drug has the
potential to be well tolerated. Alpelisib is taken orally, selec-
tively targets the a isoform of PI3K class I, and shows a minor
toxicity profile compared with pan-PI3K inhibitors. As alpe-
lisib does not completely block PI3K activity, thus main-
taining functions of the signaling pathway, it may be
particularly suitable for long-term use. Of interest, the hy-
perglycemia arising from alpelisib use may be manageable by
dietary changes.22 Because PT dysfunction is the first mani-
festation of kidney disease observed in young infants with
Dent disease 2 and Lowe syndrome, an early treatment of
such PT dysfunction, leading to improvements in the meta-
bolic profile and growth, might therefore slow progression to
chronic kidney disease and therefore have a significant impact
on lifespan and quality of life.33 Although the disease mani-
festations of OCRL mutation are particularly wide, recent
studies based on large cohorts of genotyped patients with
Lowe syndrome of Dent disease 2 did not evidence significant
effects of the type of mutation or the location of the mutation
on renal survival.34 Collectively, our data highlight the po-
tential for repurposing alpelisib for treating PT dysfunction in
Lowe syndrome/Dent disease 2, thus providing a basis for
rapid and cost-effective deployment in human clinical trials.
METHODS
Full details can be found in the Supplementary Methods.
HK2 cells were treated with copanlisib, alpelisib, GSK2636771, or
idelalisib at indicated concentrations for 16 hours unless otherwise
stated. Proteins were extracted using standard methods from cells or
kidney tissues and western blotting performed using published or
commercially available antibodies. siRNA knockdown was per-
formed using 2 transfections 72 and 24 hours before analysis.
We used age- and gender-matched OcrlY/þ;Inpp5b/; and
OcrlY/;Inpp5b/ mouse littermates harboring BAC-INPP5B
expression. Primary cultures of mPTCs were generated from the
kidneys harvested from 8 week-old Ocrl mice and the endocytic
capacity of Ocrl mPTCs assessed by measuring albumin uptake.
Alpelisib treatments were 10 mM for 16 hours, unless otherwise
stated. Albumin uptake in mPTCs was assessed using a “pulse-chase”
protocol to assess apical binding and resultant uptake. mPTCs were
stained overnight with the appropriate primary antibody and for 45
minutes with suitable fluorophore-conjugated secondary antibodies
and/or Alexa-488 Phalloidin. PI(3)P staining on mPTCs was
performed using the FYVE domain probe. Image analysis was per-
formed with CellProfiler, using custom pipelines to measure actin/
EEA1 overlap and number of puncta, and with ImageJ to measure
immunofluorescence intensity and detected edges to calculate stress
fiber score. Quantitative data were expressed as means  standard
error of the mean. For the in vivo experiments, mice aged 6 weeks
were treated with vehicle or alpelisib 50 mg/kg body weight. Urine
was collected every 14 days and animals were sacrificed after 42 days
of treatment, with blood and kidneys harvested. The PT endocytic
capacity of Ocrl mice was examined by measuring b-lactoglobulin
uptake.
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Movie S1. Imaris 3D rendering of EEA1/actin overlap in OcrlY/þ mPTCs
treated with DMSO. Representative 3D surface rendering of a
confocal stack of OcrlY/þ mPTCs treated with DMSO for 16 hours then
fixed with the 4% formaldehyde fix and immunolabelled for EEA1
(purple), actin (phalloidin; yellow), and DAPI (blue), illustrating little
actin/endosomal association. Bar ¼ 5 mm.
Movie S2. Imaris 3D rendering of EEA1/actin overlap in OcrlY/ mPTCs
treated with DMSO. Representative 3D surface rendering of a
confocal stack of OcrlY/– mPTCs treated with DMSO for 16 hours then
fixed with the 4% formaldehyde fix and immunolabelled for EEA1
(purple), actin (phalloidin; yellow), and DAPI (blue), illustrating
punctate actin associating near endosomal structures. Bar ¼ 5 mm.
Movie S3. Imaris 3D rendering of EEA1/actin overlap in OcrlY/ mPTCs
treated with alpelisib. Representative 3D surface rendering of a confocal
stack of OcrlY/– mPTCs treated with 10 mM of alpelisib for 16 hours then
fixed with the 4% formaldehyde fix and immunolabelled for EEA1
(purple), actin (phalloidin; yellow), and DAPI (blue), illustrating rescue of
actin punctate structures around endosomes. Bar ¼ 5 mm.
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